Blog

Artificial intelligence is fundamentally reshaping our approach to clinical trials by accelerating protocol development, reducing costly amendments, and improving the predictability of study outcomes. This article demonstrates how AI and in silico methods strategically augment human expertise throughout every stage of trial design, especially in high-complexity areas such as ...

In clinical research, the sheer volume of data generated across patient populations, safety endpoints, and operational metrics can overwhelm even the most experienced teams. Data visualization transforms this complexity into clarity, revealing the patterns, trends, and stories that remain invisible in raw, numeric form. Worldwide Clinical Trials has fostered a people-centric ...

The FDA’s updates to Project Optimus are shifting how researchers are approaching oncology clinical trials. Emphasizing changes in the early phase, where they now expect optimal dose data rather than the maximum tolerated dose, and randomized trials, we are seeing a change in the approach to oncology development strategy. The oncology development strategy must also account fo...

Current best practices for operationalizing early phase global oncology trials require a shift in our approach. There are challenges associated with updated regulatory guidance, including Project Optimus, which requires maximum tolerated doses to be established earlier in the clinical development pathway. We are now seeing a shift toward multi-region clinical trials where the...

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and ultimately fatal lung disease that extends its impact far beyond the respiratory system. Emerging evidence reveals significant associations between IPF and neurological complications, including cognitive decline, depression, and neurodegenerative disorders. The chronic hypoxemia and systemic inflammation chara...